CanSino Biologics has received approval from Russia to begin Phase 3 human trials for its Covid-19 vaccine candidate, Ad5-nCoV. The company will partner with a Russian firm and plans to recruit 40,000 volunteers across several countries, including Russia, Saudi Arabia, and Mexico.
This development follows CanSino's unexplained termination of a vaccine cooperation agreement with Canada's National Research Council. The company also plans to build a facility with an annual production capacity of 200 million vaccine doses.
The main topics covered are CanSino's international vaccine trials, the end of its Canadian partnership, and its production plans.
Advertisement
CanSino gets Russia’s approval to start Covid-19 vaccine trials on humans after snubbing Canada
- Approval from Moscow comes after CanSino ended a cooperation with Canada’s National Research Council for unexplained reasons
- Company plans to build a facility capable of producing 200 million doses of vaccine annually, co-founder Yu Xuefeng says
2-MIN READ2-MIN
CanSino Biologics, which developed a Covid-19 vaccine candidate with the Chinese military’s research arm, will start testing its vaccine candidate on humans in Russia as part of its global search for the coronavirus cure.
The drug maker has initiated phase three of human trials for its Ad5-nCoV vaccine candidate after receiving the green light from the health ministry in Moscow, it said in a statement on Wednesday. It will partner NPO Petrovax Pharm for the clinical trials.
The move sparked a rally in CanSino shares in Shanghai and put it in touch with global pharmaceutical firms such as AstraZeneca, which is working with the University of Oxford, in the race for the vaccine. Pfizer and its German partner BioNTech are seeking a regulatory review on their BNT162b2 vaccine candidate as early as October.
Advertisement
“The company is currently driving the international multi-centre phase three clinical trial for Ad5-nCoV and plans to conduct the clinical trial for Ad5-nCoV in several countries,” it said in the statement. It plans to recruit 40,000 volunteers in countries including Russia, Saudi Arabia, Pakistan and Mexico.
Advertisement
The Covid-19 disease has infected 25.65 million people worldwide and killed at least 854,700 since it was first detected in January in the epicentre of Wuhan, the capital of central Chinese province of Hubei. The Tianjin-based firm in March became the first Chinese firm to test a vaccine candidate on humans.
Today’s announcement came a week after CanSino ended a cooperation with National Research Council (NRC) of Canada on the development of the vaccine. Trials in Canada were expected in late May but were held up by Chinese customs in July without explanation.
Advertisement
Select Voice
Select Speed
1.00x
Meridiano
